As for AML, the first evidence of NK-mediated anti-leukemia effect was reported in the haploidentical T-cell depleted SCT setting, where it was demonstrated that a KIR-ligand mismatch between donor and recipient protects patients from leukemia relapse (15, 16). Here, KIR3DL1 is linked to leukemia.